Greenwich LifeSciences, Inc. – NASDAQ:GLSI
Greenwich LifeSciences stock price today
$12
+0.5
+4.35%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Greenwich LifeSciences stock price monthly change
-26.42%
month
Greenwich LifeSciences stock price quarterly change
-26.42%
quarter
Greenwich LifeSciences stock price yearly change
+4.45%
year
Greenwich LifeSciences key metrics
Market Cap | 161.70M |
Enterprise value | N/A |
P/E | -20.02 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 11.93 |
PEG ratio | 1.15 |
EPS | -0.72 |
Revenue | N/A |
EBITDA | -9.62M |
Income | -9.24M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGreenwich LifeSciences stock price history
Greenwich LifeSciences stock forecast
Greenwich LifeSciences financial statements
| Jun 2023 | 0 | -1.62M | |
|---|---|---|---|
| Sep 2023 | 0 | -2.39M | |
| Dec 2023 | 5.41K | -2.74M | -50696.55% |
| Mar 2024 | 0 | -2.47M |
| Dec 2023 | 5.41K | -2.74M | -50696.55% |
|---|---|---|---|
| Mar 2024 | 0 | -2.47M | |
| Oct 2025 | 0 | -2.18M | |
| Dec 2025 | 0 | -2.18M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 10951439 | 301.54K | 2.75% |
|---|---|---|---|
| Sep 2023 | 9149913 | 297.28K | 3.25% |
| Dec 2023 | 6994815 | 294.40K | 4.21% |
| Mar 2024 | 5510463 | 389.61K | 7.07% |
| Jun 2023 | -966.97K | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -1.80M | 0 | 0 |
| Dec 2023 | -2.15M | 0 | 0 |
| Mar 2024 | -1.78M | 0 | 299.11K |
Greenwich LifeSciences alternative data
| Aug 2023 | 3 |
|---|---|
| Sep 2023 | 3 |
| Oct 2023 | 3 |
| Nov 2023 | 3 |
| Dec 2023 | 3 |
| Jan 2024 | 3 |
| Feb 2024 | 3 |
| Mar 2024 | 3 |
| Apr 2024 | 3 |
| May 2024 | 3 |
| Jun 2024 | 3 |
| Jul 2024 | 3 |
Greenwich LifeSciences other data
1.24%
-3.95%
of GLSI is owned by hedge funds
159.86K
-511.51K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 23500 | 0 |
| Mar 2024 | 38600 | 0 |
| Apr 2024 | 3000 | 0 |
| Jun 2024 | 174825 | 0 |
| Jul 2024 | 2500 | 0 |
| Aug 2024 | 9300 | 0 |
| Sep 2024 | 1500 | 0 |
| Nov 2024 | 1000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | THOMPSON JAYE officer: VP Clinical Reg Affairs | Common Stock | 1,000 | $12.91 | $12,910 | ||
Purchase | PATEL SNEHAL director, 10 perc.. | Common Stock | 1,500 | $14.63 | $21,945 | ||
Purchase | THOMPSON JAYE officer: VP Clinical Reg Affairs | Common Stock | 800 | $13.85 | $11,080 | ||
Purchase | PATEL SNEHAL director, 10 perc.. | Common Stock | 2,000 | $13.81 | $27,620 | ||
Purchase | PATEL SNEHAL director, 10 perc.. | Common Stock | 5,500 | $13.18 | $72,490 | ||
Purchase | THOMPSON JAYE officer: VP Clinical Reg Affairs | Common Stock | 1,000 | $15.15 | $15,150 | ||
Purchase | PATEL SNEHAL director, 10 perc.. | Common Stock | 1,500 | $15.89 | $23,835 | ||
Purchase | THOMPSON JAYE officer: VP Clinical Reg Affairs | Common Stock | 1,000 | $16 | $16,000 | ||
Purchase | PATEL SNEHAL director, 10 perc.. | Common Stock | 174,825 | $14.3 | $2,499,998 | ||
Purchase | PATEL SNEHAL director, 10 perc.. | Common Stock | 3,000 | $19.08 | $57,240 |
| Insider | Compensation |
|---|---|
| Mr. Snehal S. Patel (1964) Chief Executive Officer, Chief Financial Officer & Director | $507,480 |
-
What's the price of Greenwich LifeSciences stock today?
One share of Greenwich LifeSciences stock can currently be purchased for approximately $12.
-
When is Greenwich LifeSciences's next earnings date?
Unfortunately, Greenwich LifeSciences's (GLSI) next earnings date is currently unknown.
-
Does Greenwich LifeSciences pay dividends?
No, Greenwich LifeSciences does not pay dividends.
-
How much money does Greenwich LifeSciences make?
Greenwich LifeSciences has a market capitalization of 161.70M.
-
What is Greenwich LifeSciences's stock symbol?
Greenwich LifeSciences, Inc. is traded on the NASDAQ under the ticker symbol "GLSI".
-
What is Greenwich LifeSciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Greenwich LifeSciences?
Shares of Greenwich LifeSciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Greenwich LifeSciences's key executives?
Greenwich LifeSciences's management team includes the following people:
- Mr. Snehal S. Patel Chief Executive Officer, Chief Financial Officer & Director(age: 61, pay: $507,480)
-
How many employees does Greenwich LifeSciences have?
As Jul 2024, Greenwich LifeSciences employs 3 workers.
-
When Greenwich LifeSciences went public?
Greenwich LifeSciences, Inc. is publicly traded company for more then 4 years since IPO on 25 Sep 2020.
-
What is Greenwich LifeSciences's official website?
The official website for Greenwich LifeSciences is greenwichlifesciences.com.
-
Where are Greenwich LifeSciences's headquarters?
Greenwich LifeSciences is headquartered at Building 14, Stafford, TX.
-
How can i contact Greenwich LifeSciences?
Greenwich LifeSciences's mailing address is Building 14, Stafford, TX and company can be reached via phone at 832 819 3232.
Greenwich LifeSciences company profile:
Greenwich LifeSciences, Inc.
greenwichlifesciences.comExchange:
NASDAQ
Full time employees:
3
Industry:
Biotechnology
Sector:
Healthcare
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Building 14
Stafford, TX 77477
Stafford, TX 77477
CIK: 0001799788
ISIN: US3968791083
CUSIP: 396879108
